{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:30:41Z","timestamp":1793727041745,"version":"4.6.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In clinical practice the diagnosis of diabetic foot osteomyelitis (DFO) relies on cultures of bone or ulcer bed (UB) biopsies, of which bone biopsy is reference standard. The slow growth or fastidious nature of some bacteria, hamper expeditious detection and identification. Rapid molecular techniques may solve both issues, but their additional value for everyday practice is unknown.<\/jats:p>\n                <jats:p>We investigated the concordance between conventional culture, the molecular techniques Molecular Culture (MC), and illumina 16S rRNA gene amplicon (16S) sequencing in people with DFO.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In the BeBoP trial, bone and UB biopsies were obtained from people with DFO who visited Amsterdam UMC. These biopsies were analysed using 1) conventional culture, 2)MC, a rapid broad range PCR analysing the 16S-23S ribosomal-interspace-region, and 3) 16S sequencing, and evaluated concordance among these techniques.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We analysed 20 samples (11 bone and 9 UB) of 18 people. A total of 84 infectious agents were identified, 45 (54%) by all techniques, an additional 22 (26.5%, overall 80.5%) by both MC and 16S, and the remaining 16 species by culture and MC or 16S, or by a single method only. MC and 16S identified anaerobes not detected by culturing in 5 samples, and the presence of bacteria in 7 of 8 culture-negative (6 bone, 2 UB) samples.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The high level of concordance between MC and 16S and the additional ability of molecular techniques to detect various bacteria not detected by culturing opens up prospects for routine use of fast molecular techniques, in clinical settings including DFO.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>The BeBoP trial is retrospectively registered on 05\u201303-2019 in Netherlands Trial Register: NL 7582.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-08472-w","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:02:14Z","timestamp":1690848134000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Concordance between culture, Molecular Culture and Illumina 16S rRNA gene amplicon sequencing of bone and ulcer bed biopsies in people with diabetic foot osteomyelitis"],"prefix":"10.1186","volume":"23","author":[{"given":"Meryl Cinz\u00eda Tila Tamara","family":"Gramberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Knippers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimke Sabine","family":"Lagrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarne Marijn","family":"van Hattem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus Christofoor","family":"de Goffau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andries Edward","family":"Budding Budding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Davids","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Matamoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Nieuwdorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin den","family":"Heijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise Willy Elizabeth","family":"Sabelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar Josephus Gerardus","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,1]]},"reference":[{"issue":"1","key":"8472_CR1","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1186\/s12879-021-06516-7","volume":"21","author":"KE Macdonald","year":"2021","unstructured":"Macdonald KE, Boeckh S, Stacey HJ, Jones JD. The microbiology of diabetic foot infections: a meta-analysis. BMC Infect Dis. 2021;21(1):770.","journal-title":"BMC Infect Dis"},{"issue":"12","key":"8472_CR2","doi-asserted-by":"publisher","first-page":"iii","DOI":"10.3310\/hta10120","volume":"10","author":"EA Nelson","year":"2006","unstructured":"Nelson EA, O\u2019Meara S, Craig D, Iglesias C, Golder S, Dalton J, et al. A series of systematic reviews to inform a decision analysis for sampling and treating infected diabetic foot ulcers. Health Technol Assess. 2006;10(12):iii\u2013iv ix-x, 1\u2013221.","journal-title":"Health Technol Assess."},{"issue":"4","key":"8472_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1464-5491.2006.01830.x","volume":"23","author":"S O'Meara","year":"2006","unstructured":"O\u2019Meara S, Nelson EA, Golder S, Dalton JE, Craig D, Iglesias C. Systematic review of methods to diagnose infection in foot ulcers in diabetes. Diabet Med. 2006;23(4):341\u20137.","journal-title":"Diabet Med"},{"issue":"Suppl 1","key":"8472_CR4","volume":"36","author":"BA Lipsky","year":"2020","unstructured":"Lipsky BA, Senneville \u00c9, Abbas ZG, Arag\u00f3n-S\u00e1nchez J, Diggle M, Embil JM, et al. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diabetes Metab Res Rev. 2020;36(Suppl 1): e3280.","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"8472_CR5","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1186\/s13063-021-05472-6","volume":"22","author":"M Gramberg","year":"2021","unstructured":"Gramberg M, Lagrand RS, Sabelis LWE, den Heijer M, de Groot V, Nieuwdorp M, et al. Using a BonE BiOPsy (BeBoP) to determine the causative agent in persons with diabetes and foot osteomyelitis: study protocol for a multicentre, randomised controlled trial. Trials. 2021;22(1):517.","journal-title":"Trials"},{"issue":"10","key":"8472_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003326","volume":"3","author":"SE Dowd","year":"2008","unstructured":"Dowd SE, Wolcott RD, Sun Y, McKeehan T, Smith E, Rhoads D. Polymicrobial nature of chronic diabetic foot ulcer biofilm infections determined using bacterial tag encoded FLX amplicon pyrosequencing (bTEFAP). PLoS ONE. 2008;3(10): e3326.","journal-title":"PLoS ONE"},{"issue":"3","key":"8472_CR7","doi-asserted-by":"publisher","first-page":"923","DOI":"10.2337\/db12-0771","volume":"62","author":"SE Gardner","year":"2013","unstructured":"Gardner SE, Hillis SL, Heilmann K, Segre JA, Grice EA. The neuropathic diabetic foot ulcer microbiome is associated with clinical factors. Diabetes. 2013;62(3):923\u201330.","journal-title":"Diabetes"},{"issue":"3","key":"8472_CR8","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.cmi.2018.04.036","volume":"25","author":"K Johani","year":"2019","unstructured":"Johani K, Fritz BG, Bjarnsholt T, Lipsky BA, Jensen SO, Yang M, et al. Understanding the microbiome of diabetic foot osteomyelitis: insights from molecular and microscopic approaches. Clin Microbiol Infect. 2019;25(3):332\u20139.","journal-title":"Clin Microbiol Infect"},{"issue":"17","key":"8472_CR9","doi-asserted-by":"publisher","first-page":"5112","DOI":"10.1128\/AEM.01043-13","volume":"79","author":"JJ Kozich","year":"2013","unstructured":"Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. Appl Environ Microbiol. 2013;79(17):5112\u201320.","journal-title":"Appl Environ Microbiol"},{"issue":"1","key":"8472_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12915-014-0087-z","volume":"12","author":"SJ Salter","year":"2014","unstructured":"Salter SJ, Cox MJ, Turek EM, Calus ST, Cookson WO, Moffatt MF, et al. Reagent and laboratory contamination can critically impact sequence-based microbiome analyses. BMC Biol. 2014;12(1):87.","journal-title":"BMC Biol"},{"issue":"4","key":"8472_CR11","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1128\/JCM.02886-15","volume":"54","author":"AE Budding","year":"2016","unstructured":"Budding AE, Hoogewerf M, Vandenbroucke-Grauls CM, Savelkoul PH. Automated Broad-Range Molecular Detection of Bacteria in Clinical Samples. J Clin Microbiol. 2016;54(4):934\u201343.","journal-title":"J Clin Microbiol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08472-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08472-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08472-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:02:16Z","timestamp":1690848136000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08472-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8472"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08472-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,1]]},"assertion":[{"value":"11 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The BeBoP trial (including the present study) has been approved by an independent ethics committee of the sponsor, Amsterdam University Medical Centres location VUmc (reference number 2018.394) on February 12, 2019. All participants of the BeBoP trial gave informed consent for the randomised trial, and additional consent for the usage of their bodily materials for the present study. All methods carried out in the BeBoP trial and in the present study were in accordance with relevant guidelines and regulations and the declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent for participation"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors state that they have no conflicts of interest, except for dr. AE Budding (owner of InBiome).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"505"}}